Back to top
more

Geron (GERN)

(Real Time Quote from BATS)

$1.52 USD

1.52
1,212,596

-0.01 (-0.65%)

Updated Aug 27, 2026 10:53 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.80%
2Buy18.13%
3Hold10.19%
4Sell5.73%
5Strong Sell3.17%
S&P50011.53%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 36% (158 out of 247)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

J&J's (JNJ) Erdafitinib Gets Breakthrough Therapy Status

by Zacks Equity Research

The breakthrough therapy designation for J&J's (JNJ) erdafitinib was based on efficacy findings from a phase II study, evaluating it in advanced urothelial cancer.

    Zacks Equity Research

    What's in the Cards for Geron (GERN) This Earnings Season?

    by Zacks Equity Research

    With no approved product in Geron's (GERN) portfolio, investor focus is likely to remain on its sole pipeline candidate, imetelstat, in the Q4 release.

      Zacks Equity Research

      Geron (GERN) Q3 Loss Narrower Than Expected, Sales Miss

      by Zacks Equity Research

      Geron's (GERN) loss per share in the third quarter was narrower than expected. However, revenues missed estimates. Imetelstat remains in focus.

        Zacks Equity Research

        Geron (GERN) in Focus: Stock Moves 9.2% Higher

        by Zacks Equity Research

        Geron (GERN) saw its shares rise over 9% on the day after the company received Fast Track designation from the U.S. Food and Drug Administration (FDA) for its experimental blood-cancer medicine, imetelstat.

          Zacks Equity Research

          What's in the Cards for Geron (GERN) this Earnings Season?

          by Zacks Equity Research

          With no approved product in Geron's (GERN) portfolio, investor focus is likely to remain on its sole pipeline candidate, imetelstat, in the Q3 release.

            Zacks Equity Research

            Geron's (GERN) Imetelstat Progressing Well, Setbacks Concern

            by Zacks Equity Research

            Geron Corporation's (GERN) telomerase inhibitor, imetelstat, is being evaluated in two late stage studies. The candidate is progressing well in the Janssen sponsored studies.

              Zacks Equity Research

              Geron (GERN) Q2 Loss Narrows, Sales Miss Estimates, Stock Up

              by Zacks Equity Research

              Geron Corporation (GERN) reported narrower-than-expected loss in Q2 while sales missed estimates. Shares were up in after-hours trading.

                Zacks Equity Research

                What's in the Cards for Geron (GERN) this Earnings Season?

                by Zacks Equity Research

                Investors will be looking at Geron's progress with its hematologic myeloid malignancies pipeline candidate, Imetelstat.

                  Zacks Equity Research

                  Why Geron (GERN) Might Be a Diamond in the Rough

                  by Zacks Equity Research

                  Geron (GERN) sees solid earnings estimate revisions and looks poised to shock the market, and yet seems overlooked by the investors.

                    Zacks Equity Research

                    Geron Stock Up Almost 40% So Far This Year After '16 Decline

                    by Zacks Equity Research

                    Geron Corporation's (GERN) shares have risen 38.7% this year so far, outperforming the Zacks classified Medical - Biomedical and Genetics industry, which rose 5.6%. This comes after a decline of more than 57% in 2016.